Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study.

INTRODUCTION: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who had serious bleeding (Group A) or required an urgent procedure (Group B).
METHODS: The primary endpoint was the incidence of adverse drug reactions (ADRs). The secondary endpoint was the maximum extent of reversal of the anticoagulant effect of dabigatran based on activated partial thromboplastin time (aPTT) within 4 h after idarucizumab administration.
RESULTS: This interim analysis included 262 patients who received idarucizumab. Eighteen patients (6.9%) experienced ADRs within 4 weeks. The reversal effect of idarucizumab based on aPTT within 4 h after idarucizumab administration was assessed in 30 patients and the median maximum percentage reversal was 100%. In Group A, the median time to bleeding cessation in patients without intracranial bleeding was 3.3 h. In Group B, normal intraoperative hemostasis was reported in 63 patients (72.4%).
CONCLUSIONS: The results of this interim analysis suggest that idarucizumab is safe and effective for the reversal of dabigatran in Japanese patients in a real-world setting, and support the continued use of idarucizumab. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02946931.

Key Summary Points

Introduction

Dabigatran etexilate (dabigatran) is an oral thrombin inhibitor approved for the prevention of stroke in patients with nonvalvular atrial fibrillation [1]. Clinical trials and post-marketing surveillance (PMS) studies, including those in Japanese and Asian populations, have shown the effectiveness and safety of dabigatran compared with warfarin [2-6]. Dabigatran is associated with fewer bleeding events than warfarin [7] and in particular, fewer events of intracranial hemorrhage for both approved doses. However, anticoagulant reversal is central to the management of uncontrolled bleeding in anticoagulated patients and, where possible, in those on anticoagulants who require emergency surgery or other invasive procedures.

Idarucizumab was developed to specifically reverse the anticoagulant effects of dabigatran during uncontrolled bleeding or emergency surgery. It is a humanized antibody fragment that specifically binds unbound and thrombin-bound dabigatran and its active glucuronide metabolites [8]. As idarucizumab is specific to dabigatran, it does not promote or inhibit thrombosis [9, 10]. Phase I studies in Caucasian and Japanese subjects [9, 11, 12] and the global phase III study (RE-VERSE AD) [13] showed that idarucizumab rapidly reverses the anticoagulant effect of dabigatran.

Based on RE-VERSE AD, idarucizumab was shown to be effective for dabigatran reversal among patients who have uncontrolled bleeding or will be undergoing urgent surgery. Idarucizumab was approved in the US [14] and EU [15] in 2015, and it was approved in Japan [16] in September 2016, and became available from November onward. An all-case PMS is in progress to collect data from Japanese patients treated with idarucizumab as requested by the Japanese authority, because a limited number of Japanese patients were treated in clinical trials for the new drug application.

Here, we present the interim results of this all-case PMS. The objective of this PMS is to assess the safety and effectiveness of idarucizumab when used according to the Japanese package insert in a Japanese clinical setting, and to investigate the characteristics of patients treated with idarucizumab.

Methods

Ethical Statement

This PMS study is fully compliant with Japanese Good Post-marketing Study Practice regulations. The protocol was approved by the Ministry of Health, Labour and Welfare of the Japanese Government. This study involved the collection of anonymous data from clinical settings and, therefore, it was not necessary to obtain informed consent from patients. All medical institutions who agreed to provide these anonymized data signed a contract with Nippon Boehringer Ingelheim Co., Ltd.

Study Design

This PMS is a multicenter, open-label, uncontrolled, all-case, non-interventional surveillance (Fig. 1). The target number of patients is 300, but registration will continue until the conditions of the approval are satisfied according to the Japanese authority. Enrollment began in November 2016. All sites in Japan in which idarucizumab has been administered are included. This study was registered with ClinicalTrials.gov (NCT02946931).

Fig. 1

Study design. The treatment period was specified as 5 days after administration. aPTT activated partial thromboplastin time

Patients

This study includes all patients treated with idarucizumab (according to the Japanese package insert) after idarucizumab was approved in Japan. Patients are classed into two groups: Group A includes patients who present life-threatening or uncontrolled bleeding, and Group B includes patients undergoing emergency surgery or an invasive procedure where significant bleeding is anticipated. According to the Japanese package insert, idarucizumab is given intravenously at 5 g/dose (2 × 2.5 g/50 ml) as two consecutive infusions over 5–10 min each or as a bolus injection. Patients are registered using paper forms, which are faxed to the sponsor. There are no exclusion criteria. Observations were made at the following time points: baseline before the first administration, during drug administration, 48 h after drug administration, and 4 weeks after drug administration or discontinuation.

Study Endpoints

The primary endpoint is the incidence of adverse drug reactions (ADRs). The secondary endpoint is the maximum extent of reversal of the anticoagulant effect of dabigatran based on activated partial thromboplastin time (aPTT) within 4 h after idarucizumab administration. A 100% reversal was defined as any value below the upper limit of normal range used by each participating hospital. Other endpoints include serious adverse events (AEs), hypersensitivity and thrombotic events, time to recorded cessation of bleeding since first infusion (in patients who developed life-threatening or uncontrolled bleeding; Group A), periprocedural hemostasis (in patients who required emergency surgery or an urgent invasive procedure; Group B), frequency of restarting anticoagulant therapy, time to restart of anticoagulant therapy, and re-exposure of patients to idarucizumab.

Data Collection and Management

Physicians use paper case report forms (CRFs) to collect patient data. Data are recorded as soon as possible after the medical examination and at the specified points (baseline, idarucizumab administration, 48 h after administration, and at 4 weeks or discontinuation). The data collected are summarized here and more details of observations and evaluations can be found in Table S1 in the Supplementary Information. Data include patient background, bleeding assessment, surgery/intervention, idarucizumab administration, coagulation tests, concomitant medications/therapy, blood pressure and pulse rate, laboratory tests, AEs, and restart of anticoagulant therapy. Data are being managed by CAC Croit Corporation (Tokyo, Japan).

Data Analysis

The safety analysis for this interim report included all patients who were registered, received idarucizumab, and who had available CRFs. AEs were coded using Version 20.0 of the Medical Dictionary for Regulatory Activities (MedDRA®) [17], the international medical terminology developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. All AEs were recorded from the first administration of idarucizumab (i.e., baseline visit) to 4 weeks after the first administration. ADRs were defined as AEs that the investigator or sponsor assessed as related to idarucizumab.

The effectiveness analysis included all patients in the safety analysis who had at least one item of available effectiveness data. The effectiveness analysis items included: extent of reversal anticoagulation effect assessed by aPTT, time to recorded cessation of bleeding since first infusion (Group A), periprocedural hemostasis (Group B), frequencies of restarting anticoagulant therapy, and time to restart anticoagulant therapy.

Statistical Analysis

It was estimated that 250–300 cases were required to ensure the same accuracy of the estimation [95% confidence interval: 2.8–9.0% (thrombosis), 8.4–17.1% (hypersensitivity)] in the Report on the Deliberation Results from the Japanese Ministry of Health, Labour & Welfare [16] Additionally, in a sample size of 300 patients, any ADR with a frequency of 1% or higher can be detected with a probability of 95% or greater in at least one patient. Descriptive statistics were used and included means, standard deviations, ranges, medians and interquartile ranges (IQR), frequencies, and percentages.

Results

Patient Characteristics

From November 2016 through April 2018, 347 patients have been enrolled and CRFs have been collected from 262 patients across 191 medical institutions (Fig. 2). The safety analysis included 262 patients (178 in Group A and 88 in Group B) and the effectiveness analysis included 259 patients (177 in Group A and 87 in Group B). Five patients were included in both Groups A and B; one patient diagnosed with abnormal coagulation accompanied by severe multi-organ disorder was classified as “other” (neither Group A nor B). In this study, enrollment of patients in Group A, Group B, or “other” was determined by the investigators. The key demographic characteristics of patients are shown in Table 1. The median age was 78.0 years, 82.8% of patients were aged 70 years or older. The median creatinine clearance was 49.0 ml/min. Overall, the duration of dabigatran use was unknown in slightly more than half (53.4%) of patients. The daily dabigatran dose was 220 mg and 300 mg in 66.0% and 16.4% of patients, respectively. The median patient-reported time from the last dose of dabigatran to the first infusion of idarucizumab was 9.4 h in Group A and 8.6 h in Group B. Overall, baseline coagulation tests were carried out in 76.3% of the patients. aPTT prolongation at baseline was reported in 47.7% of the patients.

Fig. 2

Patient disposition. Group A included patients who had uncontrolled bleeding, and Group B included patients who required urgent surgery or intervention. *Five patients were included in both Groups A and B. †One patient was classified as “other” (neither Group A nor B). This patient was prescribed idarucizumab for abnormal coagulation accompanied by severe multi-organ disorder. CRF case report form

Table 1

Baseline characteristics

Characteristic	Group A (n = 178)	Group B (n = 88)	Totala (n = 262)
Age, years
Median [range]b	78.0 [52–101]	79.0 [44–93]	78.0 [44–101]
Age ≥ 70	148 (83.2)	73 (83.0)	217 (82.8)
Age class
< 65	11 (6.2)	8 (9.1)	19 (7.3)
65 – < 75	47 (26.4)	19 (21.6)	66 (25.2)
75 – < 85	80 (44.9)	39  (44.3)	118 (45.0)
≥85	38 (21.4)	22 (25.0)	57 (21.8)
Missing	2 (1.1)	0 (0.0)	2 (0.8)
Sex, male	115 (64.6)	64 (72.7)	176 (67.2)
BMIc, kg/m2
Mean ± SD	22.2 ± 3.6	22.6 ± 4.1	22.4 ± 3.7
Creatinine clearance, ml/min
Median [range]d	50.0 [2.8–150.9]	48.8 [4.1–149.0]	49.0 [2.8–150.9]
Distribution
≥ 80	23 (12.9)	10 (11.4)	33 (12.6)
50 – < 80	44 (24.7)	15 (17.1)	58 (22.1)
30 – < 50	35 (19.7)	21 (23.9)	54 (20.6)
< 30	31 (17.4)	8 (9.1)	38 (14.5)
Unknown	45 (25.3)	34 (38.6)	79 (30.2)
Daily dose of dabigatran,
150 mg twice daily	28 (15.7)	16 (18.2)	43 (16.4)
110 mg twice daily	120 (67.4)	55 (62.5)	173 (66.0)
Other	4 (2.3)	3 (3.4)	7 (2.7)
Unknown/Missing	26 (14.6)	14 (15.9)	39 (14.9)
Duration of dabigatran use, days
< 14	31 (17.4)	18 (20.5)	48 (18.3)
14 – < 30	5 (2.8)	2 (2.3)	7 (2.7)
30 – < 91	8 (4.5)	2 (2.3)	10 (3.8)
≥91	41 (23.0)	17 (19.3)	57 (21.8)
Unknown/Missing	93 (52.2)	49 (55.7)	140 (53.4)
Time from last dabigatran dose to first administration of idarucizumab, hours
Median [range]e	9.4 [0.0–133.3]	8.6 [0.0–31.0]	9.1 [0.0–133.3]
Distribution
< 12	52 (29.2)	27 (30.7)	77 (29.4)
12 – < 24	20 (11.2)	10 (11.4)	30 (11.5)
24 – < 48	10 (5.6)	5 (5.7)	15 (5.7)
≥48	1 (0.6)	0 (0.0)	1 (0.4)
Exact timing unknown	95 (53.3)	46 (52.3)	139 (53.1)
Day before administration of idarucizumab	35 (19.7)	21 (11.8)	56 (21.4)
Day of administration of idarucizumab	32 (18.0)	13 (14.8)	44 (16.8)
≥2 days before administration of idarucizumab	4 (2.2)	1 (1.1)	5 (1.9)
Unknown/Missing	24 (13.5)	11 (12.5)	34 (13.0)
Departmentf
Neurosurgery	63 (35.4)	42 (47.7)	100 (38.2)
Cardiovascular	40 (22.5)	7 (8.0)	47 (17.9)
Emergency	29 (16.3)	4 (4.6)	34 (13.0)
Neurology	12 (6.7)	5 (5.7)	17 (6.5)
Gastroenterology	8 (4.5)	3 (3.4)	11 (4.2)
Other	28 (15.7)	28 (31.8)	56 (21.4)
Performed coagulation test	149 (83.7)	55 (62.5)	200 (76.3)
Elevated aPTT at baseline
> ULN in each site	88 (49.4)	38 (43.2)	125 (47.7)
≤ULN in each site	54 (30.3)	15 (17.1)	66 (25.2)
Unknown	36 (20.2)	35 (39.8)	71 (27.1)
PT-INR, median [range]g	1.3 [0.9–27.7]	1.3 [1.0–2.91]	1.3 [0.9–27.7]
Fibrinogen, mg/dl, median [range]h	282.0 [107.0–936.0]	297.0 [129.0–795.0]	286.0 [107.0–936.0]
Fibrin degradation products, µg/ml, median [range]i	5.8 [0.6–173.6]	8.2 [2.2–183.6]	6.0 [3.5–183.6]
D-dimer, ng/dl, median [range]j	1.6 [0.0–89.8]	1.3 [0.5–35.9]	1.4 [0.0–89.8]
Coexisting condition
Hypertension	93 (52.3)	46 (52.3)	135 (51.5)
Congestive heart failure	6 (3.4)	4 (4.6)	9 (3.4)
Diabetes	39 (21.9)	14 (15.9)	50 (19.1)
Previous stroke	4 (2.3)	0 (0.0)	4 (1.5)
Previous TIA	1 (0.6)	0 (0.0)	1 (0.4)
Previous systemic embolism	3 (1.7)	0 (0.0)	3 (1.2)
Concomitant treatment with antiplatelet drug	25 (14.0)	10 (11.4)	34 (13.0)

Data are shown as n (%) except where otherwise specified

Group A, patients with uncontrolled bleeding; Group B, patients requiring urgent surgery or intervention. Five patients were included in both Group A and Group B

BMI body mass index, aPTT activated partial thromboplastin time, ULN upper limit of normal, PMS post-marketing surveillance, PT-INR prothrombin time international normalized ratio, TIA transient ischemic attack

aTotal contains one patient who was classified as “other” (neither Group A nor B). This patient was prescribed idarucizumab for abnormal coagulation accompanied by severe multi-organ disorder

b–e,g–jData were available for 260 patients (176 in Group A, and 88 in Group B), 224 patients (150 in Group A, and 78 in Group B), 183 patients (133 in Group A, and 54 in Group B), 123 patients (83 in Group A, and 42 in Group B), 191 patients (142 in Group A, and 53 in Group B), 81 patients (59 in Group A, and 23 in Group B), 46 patients (37 in Group A, and 9 in Group B), 108 patients (84 in Group A, and 28 in Group B), respectively

fPatients may have been treated in more than one department

Of the 178 patients in Group A, 84 (47.2%) had intracranial bleeding, 49 (27.5%) had gastrointestinal bleeding, 16 (9.0%) had intra-pericardial bleeding, and 50 (28.1%) had trauma-related bleeding (Table 2). Sixty-eight patients (38.2%) had hemodynamic instability in Group A. Eighty-eight patients were classified into Group B, and the most frequent urgent surgery/intervention was a neurological procedure in 49 patients (55.7%), followed by abdominal surgery/intervention in 18 patients (20.5%); cardiovascular surgery/intervention in 15 patients (17.0%); genitourinary surgery/intervention in three patients (3.4%); and respiratory tract surgery/intervention in two patients (2.3%) (Table 2).

Table 2

Idarucizumab indication for reversal effect of dabigatran

	Group A (n = 178)
Bleeding location
Intracranial	84 (47.2)
Subdural	34 (19.1)
Subarachnoid	25 (14.0)
Intracerebral	47 (26.4)
Gastrointestinal	49 (27.5)
Lower	26 (14.6)
Upper	18 (10.1)
Unknown	12 (6.7)
Intra-pericardial	16 (9.0)
Retroperitoneal	5 (2.8)
Intramuscular	3 (1.7)
Other	33 (18.5)
Trauma-related	50 (28.1)

Data are shown as n (%). Patients may have had more than one type of bleeding. Surgery is not identified in one patient of Group B

TAVI transcatheter aortic valve implantation, ERCP endoscopic retrograde cholangiopancreatography

Safety

ADRs within 4 weeks after administration of idarucizumab were reported in 18 patients (6.9%) (Table 3). By MedDRA System Organ Class, those most frequently reported were “Nervous system disorders” in six patients, followed by "Infections and infestations" and “Injury, poisoning and procedural complications” in three patients each. The most common events reported according to MedDRA preferred term were “subdural hematoma” in two patients, “cerebral infarction” in two patients, and other events reported in one patient each. ADRs within 5 days after administration of idarucizumab were reported in 11 patients (4.2%) and the most frequently reported was “Nervous system disorders” in four patients.

Table 3

Adverse events judged by investigators to be related to idarucizumab

	Group A (n = 178)	Group B (n = 88)	Totala (n = 262)
Any ADR	9 (5.1)	9 (10.2)	18 (6.9)
Infections and infestations	2 (1.1)	1 (1.1)	3 (1.2)
Mediastinitis	1 (0.6)	0 (0.0)	1 (0.4)
Systemic candida	1 (0.6)	0 (0.0)	1 (0.4)
Infectious pleural effusion	0 (0.0)	1 (1.1)	1 (0.4)
Nervous system disorders	3 (1.7)	3 (3.4)	6 (2.3)
Cerebral infarction	1 (0.6)	1 (1.1)	2 (0.8)
Brain stem hemorrhage	1 (0.6)	0 (0.0)	1 (0.4)
Hydrocephalus	0 (0.0)	1 (1.1)	1 (0.4)
Seizure	0 (0.0)	1 (1.1)	1 (0.4)
Embolic cerebral infarction	1 (0.6)	0 (0.0)	1 (0.4)
Cardiac disorders	2 (1.1)	0 (0.0)	2 (0.8)
Acute myocardial infarction	1 (0.6)	0 (0.0)	1 (0.4)
Cardio-respiratory arrest	1 (0.6)	0 (0.0)	1 (0.4)
Vascular disorders	0 (0.0)	1 (1.1)	1 (0.4)
Arterial occlusive disease	0 (0.0)	1 (1.1)	1 (0.4)
Respiratory, thoracic, and mediastinal disorders	1 (0.6)	0 (0.0)	1 (0.4)
Pneumonia aspiration	1 (0.6)	0 (0.0)	1 (0.4)
Gastrointestinal disorders	1 (0.6)	1 (1.1)	2 (0.8)
Abdominal discomfort	0 (0.0)	1 (1.1)	1 (0.4)
Hemorrhoidal hemorrhage	1 (0.6)	0 (0.0)	1 (0.4)
General disorders and administration site conditions	0 (0.0)	1 (1.1)	1 (0.4)
Malaise	0 (0.0)	1 (1.1)	1 (0.4)
Investigations	1 (0.6)	0 (0.0)	1 (0.4)
International normalized ratio increased	1 (0.6)	0 (0.0)	1 (0.4)
Injury, poisoning, and procedural complications	1 (0.6)	2 (2.3)	3 (1.2)
Subdural hematoma	0 (0.0)	2 (2.3)	2 (0.8)
Extradural hematoma	1 (0.6)	0 (0.0)	1 (0.4)
Subdural hemorrhage	1 (0.6)	0 (0.0)	1 (0.4)

Data are reported as n (%). ADRs were coded using Version 20.0 of the Medical Dictionary for Regulatory Activities

ADR adverse drug reaction

aTotal contains one patient who was classified as “other” (neither Group A nor B). This patient was prescribed idarucizumab for abnormal coagulation accompanied by severe multi-organ disorder

Within 4 weeks after the administration of idarucizumab, 76 patients (29.0%) reported serious AEs. The most commonly observed AEs were “pneumonia aspiration” in ten patients, followed by “subdural hematoma”, eight patients; “cerebral infarction”, seven patients; “cerebral hemorrhage”, four patients; and “brain edema”, four patients. Other serious AEs were reported in three or fewer patients. Most of the events appeared to be a worsening of the index event or a coexisting condition. No other consistent pattern emerged.

The number of deaths that occurred within 4 weeks after treatment was 40 of 262 patients; 16.5% estimated by the Kaplan–Meier method, corresponding to 29 (17.8%) in Group A and 11 (13.4%) in Group B. The number of deaths that occurred within 5 days after treatment was 19 (11.0%) in Group A and six (6.9%) in Group B. The majority of events that resulted in death appeared to be a worsening of the initial event or were associated with coexisting conditions. Table 4 shows the characteristics of patients who died in each group.

Table 4

Patients with adverse events leading to death within 5 days of idarucizumab treatment

Groupa	Age (years)	Sex	AE (PT)	Time to death (days)	Reason of administration of idarucizumab
A	74	F	Epilepsy	3	Gastrointestinal bleeding
			Pneumonia aspiration
			Cardiac failure congestive
			Brain herniation
	75	M	Respiratory failure	3	Bronchial bleeding
			Bronchial hemorrhage
	71	F	Cerebral hemorrhage	1	Intracranial bleeding
	85	M	Subdural hematoma	4	Intracranial bleeding
	82	M	Disseminated intravascular coagulation	3	Gastrointestinal, bronchial, and urinary tract bleeding
			Shock hemorrhagic
	80	M	Aortic aneurysm rupture	1	Retroperitoneal bleeding
	89	M	Embolic stroke	2	Intracranial bleeding
	78	F	Renal failure	2	Gastrointestinal bleeding
			Cardiac failure chronic
			Malignant neoplasm progression
	83	M	Subdural hematoma	3	Intracranial bleeding
	81	M	Cerebral hemorrhage	2	Intracranial bleeding
	68	M	Brain stem hemorrhage	3	Intracranial bleeding
			Brain edema
	82	F	Multiple organ dysfunction syndrome	1	Gastrointestinal bleeding
			Shock hemorrhagic
			Lower gastrointestinal hemorrhage
	83	F	Hemorrhage intracranial	4	Intracranial bleeding
	60	M	Pyelonephritis	2	Gastrointestinal bleeding
			Septic shock
	70	M	Head injury	3	Intracranial bleeding
	89	M	Pulmonary alveolar hemorrhage	3	Gastrointestinal bleeding, alveolar hemorrhage
			Respiratory failure
	84	M	Acute respiratory distress syndrome	2	Gastrointestinal bleeding
			Pneumonia aspiration
	73	F	Brain stem hemorrhage	2	Intracranial bleeding
	82	M	Road traffic accident	4	Pleural hemorrhage
			Traumatic hemorrhage
B	86	M	Peritonitis	1	Missing
	75	M	Hemorrhage	1	Blood vessel prosthesis implantation for aortic dissection
			Aortic dissection
	50	M	Hemorrhagic cerebral infarction	3	Craniotomy for intracranial bleeding
	72	F	Acute myocardial infarction	2	Blood vessel prosthesis implantation for aortic dissection
			Aortic dissection
	80	M	Sepsis	1	Colectomy
	84	M	Brain herniation	4	Craniotomy for intracranial bleeding

AEs were coded using Version 20.0 of the Medical Dictionary for Regulatory Activities

AE adverse event, F female, M male, PT preferred term

aGroup A, uncontrolled bleeding; Group B, urgent surgery

Thrombotic Events

Thrombotic events occurred in 16 of the 262 patients (6.1%; 11 in Group A and five in Group B) within 4 weeks after treatment. Only three of the 16 patients were receiving anticoagulant therapy when the events occurred. Details of patients who presented thrombotic events in each group are provided in Table 5. During the 4-week follow-up of patients treated with idarucizumab, anticoagulant therapy was restarted in 45.8% of the patients in Group A and in 61.6% in Group B (Table 6), at a median of 5.3 days and 4.6 days, respectively, after the administration of idarucizumab.

Table 5

Patients with thrombotic events occurring within 28 days after administration of idarucizumab

Groupa	Sex	Age (years)	Index event	Thrombotic event	Time to thrombotic event after treatment	Outcome	OAC
A	M	77	Urinary tract bleeding	Acute myocardial infarction	< 24 h	Recovered	No
	M	89	Intracranial hemorrhage	Embolic stroke	< 24 h	Fatal	Unknown
	M	87	Gastrointestinal bleeding	Myocardial infarction	< 24 h	Fatal	No
	F	70	Intracranial hemorrhage by trauma	Cerebral infarction	1 d	Fatal	No
	M	76	Multiple bleeding by trauma	Cerebral infarction	1 d	Recovered	Yes
	M	63	Gastrointestinal bleeding	Peripheral arterial occlusive disease	5 d	Recovered	No
	M	80	Intracranial hemorrhage by trauma	Cerebral infarction	6 d	Not recovered	No
	F	80	Intraperitoneal bleeding	Embolic cerebral infarction	7 d	Recovered	No
	F	101	Gastrointestinal bleeding	Arterial occlusive disease	9 d	Recovered	No
	F	83	Intracranial hemorrhage by trauma	Pulmonary embolism	16 d	Unknown	Yes
	M	78	Intracranial hemorrhage by trauma	Cerebral infarction	23 d	Unknown	No
B	F	72	Blood vessel prosthesis implantation for aortic dissection	Acute myocardial infarction	< 24 h	Fatal	No
	M	70	STA-MCA anastomosis for stroke	Cerebral infarction	1 d	Not recovered	No
	F	81	Thrombolysis for stroke	Cerebral infarction	2 d	Recovered	Yes
	M	57	Thrombolysis for stroke	Arterial occlusive disease	2 db	Recovered	Unknown
	F	77	Blood vessel prosthesis implantation for aortic dissection	Cerebral infarction	19 d	Fatal	No
				Carotid artery occlusion

F female, M male, OAC oral anticoagulant, STA-MCA superficial temporal artery to middle cerebral artery

aGroup A, uncontrolled bleeding; Group B, urgent surgery

bEvent may have occurred before administration but was diagnosed 2 days after treatment

Table 6

Blood product use and resumption of anticoagulant therapy

Blood product use	Group A (n = 178)	Group B (n = 88)	Totala (n = 262)
Blood products/transfusions	81 (45.5)	30 (34.1)	112 (42.8)
FFP	33 (18.5)	19 (21.6)	53 (20.2)
Packed RBCs	59 (33.2)	22 (25.0)	82 (31.3)
Platelets	13 (7.3)	12 (13.6)	26 (9.9)
Cryoprecipitate	0 (0.0)	0 (0.0)	0 (0.0)
Whole blood	0 (0.0)	0 (0.0)	0 (0.0)
PCC	1 (0.6)	0 (0.0)	1 (0.4)
Factor VIIa	0 (0.0)	0 (0.0)	0 (0.0)
Volume expanders	2 (1.1)	1 (1.1)	3 (1.2)
Tranexamic acid	24 (13.5)	2 (2.3)	26 (9.9)
Other	13 (7.3)	10 (11.4)	23 (8.8)

Data are presented as n (%)

FFP fresh frozen plasma, RBC red blood cells, PCC prothrombin complex concentrate

aTotal contains one patient who was classified as “other” (neither Group A nor B). This patient was prescribed idarucizumab for abnormal coagulation accompanied by severe multi-organ disorder

bData were available for 258 patients (177 in Group A, and 86 in Group B)

Potential Hypersensitivity

Of the AEs of special interest, potential hypersensitivity occurred in two patients in Group A, whereby circulatory collapse and urticaria were reported. These events were not considered ADRs and resolved.

Re-Exposure to Idarucizumab

Only one of the 262 patients (0.4%) received a second dose of idarucizumab (5 g) after the initial administration of idarucizumab and was later able to restart dabigatran therapy. The patient was a 73-year-old man in Group B who received an initial dose of 5 g of idarucizumab for laparoscopic cholecystectomy. Dabigatran therapy was reinitiated 40 h after the administration of idarucizumab. Forty days after the administration of idarucizumab, the patient received the second dose of idarucizumab (5 g) before undergoing urgent endoscopic retrograde cholangiopancreatography. No AEs were reported after the first or second administration of idarucizumab.

Effectiveness

aPTT

As a secondary endpoint, we evaluated the maximum reversal of the anticoagulant effect of dabigatran based on aPTT within 4 h after idarucizumab administration. The number of patients with coagulation test data at baseline was 149 (83.7%) in Group A, 55 (62.5%) in Group B, and 200 (76.3%) in total. The number of patients with aPTT prolongation at baseline was 88 (49.4%) in Group A, 38 (43.2%) in Group B, and 125 (47.7%) in total (Table 1). Only 30 patients had aPTT data at baseline and within 4 h after administration of idarucizumab, and these data were used for the calculation of the maximum reversal effect. A complete reversal effect was observed in 20 of 30 patients based on aPTT and the median maximum percentage reversal within 4 h after the administration of idarucizumab was 100%. The effectiveness of idarucizumab based on aPTT of each patient is shown in Table 7. The use of blood products and volume expanders is described in Table 6.

Table 7

Reversal effect of idarucizumab by aPTT in Groups A and B

Groupa	Bleeding/surgery	Age (years)	Sex	Time to idarucizumab from last administration of dabigatran (hours)	CrCl (ml/min)	Daily dose of dabigatran (mg)	ULN	Pre-administration aPTT (s)	Post-administration aPTT (s)	Reversal effectb(%)
A	Gastrointestinal	78	Female	Exact timing unknownc	15.4	220	39.0	112.1	31.6	100
	Gastrointestinal	78	Male	133.3	23.8	220	36.0	38.9	27.2	100
	Gastrointestinal	84	Male	15.0	22.8	220	36.0	64.8	33.3	100
	Gastrointestinal	91	Female	6.7	38.1	220	34.0	48.4	27.2	100
	Intracranial	82	Male	5.8	40.3	220	39.8	46.2	27.3	100
	Intracranial	82	Female	Unknown	45.2	220	34.5	49.3	34.1	100
	Intracranial	76	Male	13.3	54.8	220	38.0	45.7	36.0	100
	Intramuscular	74	Male	6.6	111.8	220	36.0	48	32.0	100
	Intramuscular	71	Male	9.4	87.2	220	40.0	62.4	35.0	100
	Other	76	Male	Exact timing unknownc	93.1	220	36.1	41.1	35.8	100
	Other	80	Male	Exact timing unknownc	Missing	110	39.7	44.7	37.2	100
	Other	86	Male	Exact timing unknowne	25.4	220	35.2	72.8	33.2	100
	Intracranial	81	Female	Unknown	41.9	220	40.0	91.3	37.6	100
	Gastrointestinal	78	Female	41.5	7.8	220	40.0	144	42.7	97.4
	Gastrointestinal	91	Female	Exact timing unknownc	26.4	220	39.0	152.7	58.9	82.5
	Intra-pericardial	78	Female	9.6	55.1	220	32.0	35.4	33.3	61.8
	Intracranial	85	Male	Exact timing unknownd	44.1	220	34.0	38.7	37.1	34.0
	Gastrointestinal	73	Male	Exact timing unknownc	Missing	150	38.0	50.9	47.7	24.8
	Gastrointestinal	60	Male	Unknown	101.5	300	32.0	142.1	135.6	5.9
	Gastrointestinal	66	Female	Exact timing unknownd	Missing	300	38.1	44.8	61.5	0
B	Burr hole drainage for subdural hemorrhage	73	Male	5.0	69.6	300	40.0	47.2	27.8	100
	Craniotomy for brain tumoral hemorrhage	80	Male	7.1	76.2	220	38.9	39.8	30.1	100
	Decompressive craniectomy	50	Male	12.3	90.8	220	40.0	54.9	35.8	100
	Renal failure	54	Male	Exact timing unknownc	25.9	220	35.6	58.4	23.4	100
	Cholecystectomy	81	Female	8.5	87.5	220	40.0	60.8	38.0	100
	Brain tumor resection	75	Female	31.0	67.8	75	34.3	38.5	29.6	100
	Drainage for brain abscess	85	Male	Exact timing unknownd	60.5	220	38.1	45.1	28.0	100
	Suture for gastric perforation	67	Male	Exact timing unknownd	38.3	300	35.0	98.7	43.1	87.3
	Colectomy for intestinal obstruction	80	Male	Missing	Missing	110	35.0	161.9	68.6	73.5
	Procedure for pericardial effusion	88	Male	12.9	48.8	300	25.0	63.8	40.2	60.8

Data are presented as n (%)

ULN upper limit of normal at site, aPTT activated partial thromboplastin time, CrCl creatinine clearance

aGroup A, uncontrolled bleeding; Group B, urgent surgery

bMaximum reversal is calculated as [(predose aPTT − minimum postdose aPTT)/(predose aPTT − ULN)] × 100%

cExact time to idarucizumab from last administration of dabigatran was unknown. Last dose of dabigatran was administered at the day before administration of idarucizumab

dExact time to idarucizumab from last administration of dabigatran was unknown. Last dose of dabigatran was administered at the day of administration of idarucizumab

eExact time to idarucizumab from last administration of dabigatran was unknown. Last dose of dabigatran was administered ≥ 2 days before administration of idarucizumab

Time to Cessation of Bleeding

Cessation of bleeding judged by investigators was confirmed in 119 (67.2%) of the 177 patients analyzed in Group A. Of these 119 patients, time to cessation of bleeding was reported for 100 patients. The median time to recorded cessation of bleeding was 5.8 h (IQR 1.7–19.6 h). In many intracranial hemorrhage cases, time to recorded cessation of bleeding may be more prolonged as early follow-up imaging by computed tomography or magnetic resonance imaging was not mandated in this PMS. Therefore, we also evaluated the time to recorded cessation of bleeding in 62 nonintracranial hemorrhage patients. The median time to recorded cessation of nonintracranial hemorrhage was 3.3 h (IQR 0.8–15.0 h).

Periprocedural Hemostasis

Among 87 patients in Group B who underwent surgery or an intervention, periprocedural hemostasis was determined to be normal in 63 patients (72.4%), mildly abnormal in six patients (6.9%), moderately abnormal in nine patients (10.3%), severely abnormal in five patients (5.7%), and missing in four patients (4.6%).

Discussion

For this interim analysis, demographic characteristics and the safety and effectiveness of idarucizumab were evaluated in 262 Japanese patients receiving dabigatran who had either uncontrolled bleeding or were about to undergo an urgent procedure. Idarucizumab safely and effectively resulted in the reversal of the effects of dabigatran. Eighteen patients (6.9%) experienced ADRs within 4 weeks, while the reversal effect of idarucizumab based on aPTT within 4 h after administration (assessed in 30 patients) yielded a median maximum percentage reversal of 100%. Median time to bleeding cessation in patients with uncontrolled bleeding (without intracranial bleeding) was 3.3 h, and normal intraoperative hemostasis was reported in 63/87 patients (72.4%) scheduled for urgent surgery.

While this is an interim analysis, and the study designs differ, our results to date are consistent with the results of the RE-VERSE AD study [13]. The overall median age of patients in our study was 78 years, which is the same as RE-VERSE AD [13], and more than 80% of patients treated with idarucizumab were aged ≥ 70 years. This result is consistent with the previous finding that the majority of nonvalvular atrial fibrillation patients treated with dabigatran are elderly [2]. The median creatinine clearance was 49.0 ml/min in our study; in RE-VERSE AD, 43.3% of patients had a creatinine clearance of < 50 ml/min [13]. In the present interim analysis, the exact timing of the last dose of dabigatran was unknown in approximately 50% of the patients. However, the median patient-reported time from the last dose of dabigatran to the first infusion of idarucizumab was 9.1 h, which was a shorter period of time compared with the time in RE-VERSE AD (14.6 h in Group A and 18.0 h in Group B) [13]. Most patients in our study and RE-VERSE AD received the twice-daily 110-mg dose of dabigatran.

A total of 178 patients were enrolled in Group A because of life-threatening or uncontrolled bleeding. The most common bleeding event in Group A was intracranial hemorrhage followed by gastrointestinal bleeding. Patients with intracranial hemorrhage accounted for 47.2% of cases of uncontrolled bleeding, whereas patients with gastrointestinal hemorrhage accounted for 27.5% of cases of uncontrolled bleeding. Compared with the proportion of bleeding by location in RE-VERSE AD [13], the proportion of gastrointestinal bleeding in Group A was lower, and the proportion of intracranial hemorrhage was higher in this interim analysis. This is consistent with epidemiological studies that have shown intracranial hemorrhage to be more common in Asian than non-Asian patients [18]. In cases where the source of gastrointestinal bleeding can be identified by gastrointestinal endoscopy, cessation of bleeding without administration of idarucizumab could be achieved by clipping or cauterizing the blood vessel. While there may be differences in the medical environment for treatment of gastrointestinal bleeding, most hospitals in Japan can perform endoscopy.

In Group A, 9% of patients had cardiac tamponade during catheter ablation. Cardiac tamponade is a potentially fatal complication and is among the most frequently observed complications of catheter ablation [19]. Although the results of the RE-CIRCUIT study [20] show the benefit of uninterrupted anticoagulation with dabigatran during catheter ablation, administration of idarucizumab might also be useful for patients with cardiac tamponade, as demonstrated in an idarucizumab case series in Japan [21]. In a retrospective analysis of 21 patients with cardiac tamponade who received idarucizumab, hemostasis was restored at a median of 205.6 ± 14.8 min, and no thromboembolic events had occurred within 72 h after the idarucizumab administration [21].

Group B included 88 (33.6%) patients who underwent emergency surgery or an urgent intervention. In this analysis, classification of A or B was determined by investigators, and several patients who required an emergency surgery/intervention such as craniotomy or drainage of subdural hematoma were enrolled in Group B, even if they had bleeding. The most common emergency surgery or urgent intervention was neurological, including craniotomy for intracranial hemorrhage and thrombolysis/thrombectomy for ischemic stroke, which were performed in 49 patients (55.7%). Other common emergency surgeries or urgent interventions included abdominal surgery/intervention in 18 patients (20.5%) and cardiovascular surgery/intervention in 15 patients (17.0%). In RE-VERSE AD [13], the most common urgent surgery/intervention was abdominal condition or infection, followed by fracture or septic arthritis. Compared with the reasons for surgery in RE-VERSE AD [13], the proportion of neurological surgery/intervention in Group B was higher and there was no fracture or septic arthritis in this interim analysis. This difference may be attributable to the indications of dabigatran. In Japan, dabigatran is not indicated for the prevention or treatment of venous thromboembolism. In this interim analysis, nine patients were treated with idarucizumab before treatment of ischemic stroke (thrombolysis, thrombectomy, or bypass for ischemic stroke). Several case reports suggest that thrombolysis and thrombectomy can be performed safely after dabigatran reversal with idarucizumab [22, 23]. Although these data are limited, recommendations have been published regarding acute reperfusion therapy with idarucizumab for patients with ischemic stroke receiving dabigatran [24, 25].

In this interim analysis, about 30% of the patients in Group A had trauma-related bleeding. In addition to trauma-related bleeding in Group A, several patients in Group B required emergency surgery for trauma-related injury. However, we could not evaluate the number of patients accurately because it was not mandatory to collect trauma-related data in Group B. In Group B, the most frequent event was a surgery/intervention for subdural hematoma, which was secondary to a fall. Patients receiving anticoagulant therapy are at increased risk for intracranial hemorrhage after minor head injury, even in cases where initial computed tomography scans following the injury are negative [26]. There have been reports of patients who develop life-threatening intracranial hematoma in the days following even minor traumatic brain injury [27, 28]. Therefore, a drug that can rapidly reverse the anticoagulant effect may be useful in treating such patients and preventing further injury.

ADRs, serious AEs, and AEs leading to death within 4 weeks after administration of idarucizumab were reported in 18 patients (6.9%), 76 patients (29.0%), and 40 patients (15.3%) in this interim analysis, respectively. The majority of events appeared to be a worsening of the index event or were associated with coexisting conditions; these results were similar to those of RE-VERSE AD [13]. In the present interim analysis, the rate of thrombotic events was 6.1% within 4 weeks after treatment and the rate was similar in Groups A and B (6.2 and 5.7%, respectively). Eleven patients (68.8%) who presented thrombotic events had not reinitiated anticoagulation therapy when the events occurred. The rate of restarting anticoagulation was 51.6%. This low rate of restarting anticoagulation may have contributed to the thrombotic events because thrombotic events are more likely to reflect the underlying prothrombotic state than to be a direct effect of reversal. In RE-VERSE AD [13], thrombotic events occurred in 4.8% of patients overall within 30 days after treatment. These results underscore the importance of restarting anticoagulation therapy at an appropriate time for patients in whom it is indicated.

In this interim analysis, of the 262 patients, 25.2% had a normal range of aPTT and approximately 27% were lacking aPTT data at baseline. As this was an observational study, measurement and assessment of coagulation tests before and after administration of idarucizumab were not mandatory. Idarucizumab is generally used in urgent cases. It is likely that some physicians may have decided to administer idarucizumab to patients treated with dabigatran without measurement and/or assessment of coagulation parameters to avoid a delay in treatment. In RE-VERSE AD [13], even if patients had little or no circulating dabigatran, the use of idarucizumab was shown to be safe.

In RE-VERSE AD [13], reversal of the anticoagulant effect of dabigatran was assessed based on the diluted thrombin time (dTT) or the ecarin clotting time (ECT). In Japanese clinical settings, dTT, and ECT are not available. As aPTT is available in Japanese clinical settings, the reversal effect based on aPTT measurement was chosen as a secondary endpoint in this study. The reversal effect based on aPTT was evaluated in only 30 patients (11.5%) who had aPTT data before and after treatment with idarucizumab. The aPTT values in patients after treatment were below the normal range in 20 (66.7%) of the 30 patients. The remaining ten patients still showed prolongation of aPTT values after administration of idarucizumab; these patients included those with coagulopathy due to massive bleeding or those who had received heparin during the perioperative period. Notably, aside from dabigatran treatment, these patients seemed to have other factors that contributed to prolongation of aPTT values.

Among patients with non-intracranial bleeding who could be evaluated, the median time to the cessation of bleeding was 3.3 h. In RE-VERSE AD [13], among patients with overt bleeding who could be evaluated in the first 24 h, the median time to the cessation of bleeding was 2.5 h. The time to the cessation of bleeding in our study is similar to the time to cessation of bleeding in RE-VERSE AD [13]. In Group B of RE-VERSE AD [13], 95% of patients had normal or mildly abnormal hemostasis during the procedure, which is consistent with the hemostasis observed during the procedures in this study. Therefore, the use of idarucizumab permitted safe intervention in the majority of patients.

Data related to the re-exposure to idarucizumab are lacking as evidence of re-exposure of idarucizumab is limited in clinical trials. In this interim analysis, only one of the 262 patients (0.4%) received a second dose of 5-g idarucizumab after first administration of idarucizumab and resumption of dabigatran. The reversal effect after the first and second administration of idarucizumab could not be evaluated because aPTT data were missing. Regarding safety, no AEs were reported after the first and second administration of idarucizumab. Further clinical data are needed to fully determine the impact of repeated administration of idarucizumab.

Limitations

This study has some limitations inherent to PMS studies in general. We were unable to collect detailed information such as that obtained in clinical trials. Additionally, this study lacks a control arm. Evaluation of the reversal effect is limited because there are no data on the concentration of dabigatran, dTT, and ECT. The 4-week observation period could not be completed for some patients due to hospital discharge or transfer. Finally, this PMS is in progress, so these interim results should be interpreted with caution.

Conclusions

The results of this interim analysis of this PMS suggest that idarucizumab can safely and effectively reverse the effects of dabigatran in Japanese patients in real-world clinical practice. The safety and effectiveness data support the continued use of idarucizumab, and no new safety concerns have been identified thus far. These interim findings, based on the data from 262 patients, further corroborate the favorable safety profile of idarucizumab as previously shown in RE-VERSE AD.

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 25 kb)

Why carry out this study?

Patients who are receiving long-term anticoagulation with dabigatran may require rapid reversal of the anticoagulant in the event of severe bleeding or urgent surgery.

Idarucizumab was developed to specifically reverse the anticoagulant effects of dabigatran, and neither promotes nor inhibits thrombosis.

This post-marketing surveillance study assessed the safety and effectiveness of idarucizumab when used according to the Japanese package insert in 262 patients.

What was learned from the study?

Adverse drug reactions occurred in 18 (6.9%) patients, and the median maximum percentage reversal of idarucizumab was 100%, based on activated partial thromboplastin time within 4 h after administration.

The safety and effectiveness data from this study support the continued use of idarucizumab in Japanese clinical practice, and no new safety concerns have been identified so far.